Wells Fargo
BEAM icon

Wells Fargo’s Beam Therapeutics BEAM Stock Holding History

Wells Fargo’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.5M Buy
189,389
+57,140
+43% +$1.73M ﹤0.01% 2595
2026
Q1 		$3.15M Sell
132,249
-26,939
-17% -$747K ﹤0.01% 2936
2025
Q4 		$4.41M Buy
159,188
+41,865
+36% +$1.07M ﹤0.01% 2802
2025
Q3 		$2.85M Buy
117,323
+33,912
+41% +$675K ﹤0.01% 3063
2025
Q2 		$1.42M Sell
83,411
-53,462
-39% -$931K ﹤0.01% 3479
2025
Q1 		$2.67M Buy
136,873
+8,871
+7% +$232K ﹤0.01% 2935
2024
Q4 		$3.17M Buy
128,002
+19,158
+18% +$489K ﹤0.01% 2805
2024
Q3 		$2.67M Buy
108,844
+47,091
+76% +$1.22M ﹤0.01% 2836
2024
Q2 		$1.45M Buy
61,753
+14,880
+32% +$365K ﹤0.01% 3230
2024
Q1 		$1.55M Buy
46,873
+9,927
+27% +$309K ﹤0.01% 3172
2023
Q4 		$1.01M Sell
36,946
-61,174
-62% -$1.52M ﹤0.01% 3424
2023
Q3 		$2.36M Buy
98,120
+12,471
+15% +$334K ﹤0.01% 2673
2023
Q2 		$2.73M Buy
85,649
+26,076
+44% +$846K ﹤0.01% 2637
2023
Q1 		$1.82M Buy
59,573
+43,014
+260% +$1.7M ﹤0.01% 2938
2022
Q4 		$648K Sell
16,559
-4,448
-21% -$199K ﹤0.01% 3486
2022
Q3 		$1M Sell
21,007
-54,017
-72% -$3.08M ﹤0.01% 3248
2022
Q2 		$2.9M Sell
75,024
-14,505
-16% -$577K ﹤0.01% 2497
2022
Q1 		$5.13M Buy
89,529
+23,406
+35% +$1.54M ﹤0.01% 2438
2021
Q4 		$5.27M Buy
66,123
+11,336
+21% +$971K ﹤0.01% 2517
2021
Q3 		$4.77M Sell
54,787
-3,483
-6% -$350K ﹤0.01% 2873
2021
Q2 		$7.5M Buy
58,270
+12,636
+28% +$1.01M ﹤0.01% 2475
2021
Q1 		$3.65M Buy
45,634
+7,432
+19% +$707K ﹤0.01% 3151
2020
Q4 		$3.12M Buy
38,202
+5,151
+16% +$253K ﹤0.01% 3154
2020
Q3 		$814K Buy
33,051
+18,508
+127% +$459K ﹤0.01% 4011
2020
Q2 		$407K Buy
14,543
+6,640
+84% +$143K ﹤0.01% 4477
2020
Q1 		$142K Buy
+7,903
New +$172K ﹤0.01% 4883

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Wells Fargo's BEAM Position: Q2 2026 in Review

Wells Fargo increased its Beam Therapeutics (BEAM) stake by 43% in Q2 2026, buying an estimated $1.73M and bringing the position to 189,389 shares worth $6.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2595.

Wells Fargo first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $7.5M in Q2 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Wells Fargo held 189,389 shares of Beam Therapeutics worth $6.5M as of Q2 2026.
  • Wells Fargo bought 57,140 Beam Therapeutics shares in Q2 2026, an estimated $1.73M.
  • Beam Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2595 holding.
  • Wells Fargo first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Wells Fargo's Beam Therapeutics position peaked at $7.5M in Q2 2021.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.